Market Newsdesk

September 28, 2023 8:15 pm

United Natural Foods Wraps Up Natural Winter Show in Las Vegas – Helps Retailers Prepare for Holiday Selling Season

United Natural Foods Wraps Up Natural Winter Show in Las Vegas – Helps Retailers Prepare for Holiday Selling Season

Company concludes successful 2023 show season; changes show schedule for 2024 season to showcase full assortment of products and services and better align with customer buying

PROVIDENCE, R.I.–(BUSINESS WIRE)–
United Natural Foods, Inc. (NYSE: UNFI) (the “Company” or “UNFI”) today completed its 2023 schedule of shows and events, concluding it with a successful Natural Winter Show in Las Vegas, NV, which wrapped up on Thursday, September 28. Throughout the two-day event more than 2,000 attendees, representing hundreds of UNFI customers from across North America, connected with UNFI’s extensive community of suppliers offering a wide-ranging assortment across grocery, fresh, organic and specialty departments. The show also featured UNFI’s Professional Services offerings to retailers, which drive traffic, save time and money, and enhance the shoppers’ experience.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230928021676/en/

Customers hear how UNFI Professional Services can help them enhance their shoppers’ in-store experience with award-winning grocery displays and innovative merchandising layouts. (Photo: Business Wire)

“The UNFI shows physically connect our community of customers and suppliers in a way that creates real value for everyone,” said Steve Dietz, Chief Customer Officer at UNFI. “This natural show really showcased the innovation and passion from our natural and organic manufacturing partners and enabled retailers to discover new items that deliver the differentiated value proposition consumers expect from their local grocer, helping them remain competitive in their marketplace.”

This year’s UNFI Natural Winter Show included:

More than 2,000 attendees, including domestic and international retailers and suppliers.
Over 580 suppliers covering more than 75,000 square feet showcasing more than 800 brands.
Hundreds of new products, with more than 40 selected and featured in UNFI’s New Product Showcase Area and more than 35 highlighted as UpNext emerging brands.
The second appearance of the UNFI Food Safety and Quality Assurance team to help retailers navigate the new FDA rules on food traceability.
UNFI Professional Services experts providing solutions in Retail Technology, Store Operations, and Retail Marketing that help retailers reduce expenses, drive revenue, and enhance their customer’s shopping experience.

“UNFI is just a terrific partner in so many aspects of our business,” said Saj Khan, VP of Grocery Operations & Purchasing at Nugget Markets. “Through events like this week’s Las Vegas show, they work alongside our team to help us identify new and trending products, source great deals, and assist in supplier negotiations that are impactful to our merchandising plans. They are instrumental to our continued growth and success.”

One of the more unique aspects of UNFI shows is the Pitch Slam competition, presented by UNFI UpNext. The UNFI UpNext team discovers and mentors emerging brands, guiding their path to growth while helping deliver UNFI customers a regionally sourced, differentiated product mix. Pitch Slam pits UpNext suppliers alongside each other in a friendly and fun elevator pitch style competition. This year’s winner of the UNFI Natural Winter Show Pitch Slam was Ruby Hibiscus Water, a sparkling organic soda.

Noah Wunsch, founder of Ruby Hibiscus, said, “I’m so unbelievably grateful for such an exceptional group to acknowledge our up and coming brand, organic sparkling hibiscus line! We believe in clean and organic ingredients, with functional benefits, and it means the world to us to see that you all do as well.”

UNFI changing its show schedule for 2024.

Beginning in January 2024, to further reinforce UNFI’s customer and supplier-focused transformation, all UNFI selling shows will support both the natural and conventional supplier and customer channels, showcasing the Company’s unique and differentiated supply chain. UNFI’s 2024 Spring and Summer shows will be held February 7-8 in San Diego (West), and February 20-21 in Orlando (Central and East). As for the UNFI Holiday and Winter shows, they’ll be held June 4-5 in Uncasville, CT (East), and August 6-7 in Minneapolis (Central and West), respectively.

For more information on UNFI Shows, customers or suppliers can visit: https://www.unfi.com/shows-events or email [email protected].

About UNFI

UNFI is North America’s premier grocery wholesaler delivering the widest variety of fresh, branded, and owned brand products to more than 30,000 locations throughout North America, including natural product superstores, independent retailers, conventional supermarket chains, ecommerce providers, and food service customers. UNFI also provides a broad range of value-added services and segmented marketing expertise, including proprietary technology, data, market insights, and shelf management to help customers and suppliers build their businesses and brands. As the largest full-service grocery partner in North America, UNFI is committed to building a food system that is better for all and is uniquely positioned to deliver great food, more choices, and fresh thinking to customers. To learn more about how UNFI is delivering value for its stakeholders, visit www.unfi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928021676/en/

For UNFI Investors:

Kristyn Farahmand

401-213-2160

[email protected]

-or-

Steve Bloomquist

952-828-4144

[email protected]

For Media:

UNFI

Charles Davis

215-539-1696

[email protected]

KEYWORDS: United States North America Rhode Island Nevada

INDUSTRY KEYWORDS: Retail Other Professional Services Data Management Technology Marketing Food Tech Communications Organic Food Professional Services Supply Chain Management Online Retail Supermarket Specialty Food/Beverage Data Analytics

MEDIA:

Logo

Photo

September 28, 2023 8:14 pm

Cal-Maine Foods, Inc. Announces Definitive Agreement to Acquire Egg Production Assets of Fassio Egg Farms, Inc.

Cal-Maine Foods, Inc. Announces Definitive Agreement to Acquire Egg Production Assets of Fassio Egg Farms, Inc.

RIDGELAND, Miss.–(BUSINESS WIRE)–
Cal-Maine Foods, Inc. (NASDAQ: CALM) (“Cal-Maine Foods” or the “Company”), the largest producer and distributor of fresh shell eggs in the United States, today announced a definitive agreement to acquire substantially all the assets of Fassio Egg Farms, Inc. (“Fassio”), related to its commercial shell egg production and processing business. The assets to be acquired, subject to the completion of this transaction, include commercial shell egg production and processing facilities with current capacity of approximately 1.2 million laying hens, primarily cage-free, feed mill, pullets, fertilizer production and composting operation and land located in Erda, Utah, outside Salt Lake City. The Company expects to close the transaction in the next few weeks, subject to customary closing conditions.

Commenting on the announcement, Sherman Miller, president and chief executive officer of Cal-Maine Foods, Inc., stated, “We are excited about the opportunity to expand our market presence in Utah and the western United States with the proposed acquisition of these assets from Fassio. The additional production capacity, especially for cage-free eggs, will enhance our ability to serve our valued customers in this important market area. Fassio has been a leader in the egg production business since 1915 and enjoys a solid reputation in the community. We look forward to working with the Fassio team as we extend our market reach and deliver greater value to both our customers and shareholders.”

About Cal-Maine Foods

Cal-Maine Foods, Inc. is primarily engaged in the production, grading, packaging, marketing and distribution of fresh shell eggs, including conventional, cage-free, organic, brown, free-range, pasture-raised and nutritionally enhanced eggs. The Company, which is headquartered in Ridgeland, Mississippi, is the largest producer and distributor of fresh shell eggs in the United States and sells the majority of its shell eggs in states across the southwestern, southeastern, mid-western and mid-Atlantic regions of the United States.

Forward Looking Statements

Statements contained in this press release that are not historical facts are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current intent, belief, expectations, estimates and projections regarding our company and our industry. These statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other factors that are difficult to predict and may be beyond our control. The factors that could cause actual results to differ materially from those projected in the forward-looking statements include, among others, (i) the risk factors set forth in the Company’s SEC filings (including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K), (ii) the risks and hazards inherent in the shell egg business (including disease, pests, weather conditions and potential for recall), including but not limited to the most recent outbreak of highly pathogenic avian influenza affecting poultry in the U.S., Canada and other countries that was first detected in commercial flocks in the U.S. in February 2022, (iii) changes in the demand for and market prices of shell eggs and feed costs, (iv) our ability to predict and meet demand for cage-free and other specialty eggs, (v) risks, changes or obligations that could result from our future acquisition of new flocks or businesses and risks or changes that may cause conditions to completing a pending acquisition not to be met, (vi) risks relating to increased costs and higher and potentially further increases in inflation and interest rates, which began in response to market conditions caused in part by the COVID-19 pandemic and which generally have been exacerbated by the Russia-Ukraine war that began in February 2022, (vii) our ability to retain existing customers, acquire new customers and grow our product mix, and (viii) adverse results in pending litigation matters. SEC filings may be obtained from the SEC or the Company’s website,www.calmainefoods.com. Readers are cautioned not to place undue reliance on forward-looking statements because, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. Further, the forward-looking statements included herein are only made as of the respective dates thereof, or if no date is stated, as of the date hereof. Except as otherwise required by law, we disclaim any intent or obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230927606265/en/

Sherman Miller, President and CEO

Max P. Bowman, Vice President and CFO

(601) 948-6813

KEYWORDS: United States North America Mississippi Utah

INDUSTRY KEYWORDS: Food/Beverage Agriculture Natural Resources Retail Supermarket

MEDIA:

Logo

September 28, 2023 8:09 pm

Medigus Announces $53.3 million in Revenues for the First Six Months of 2023

TEL AVIV, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) — Medigus Ltd. (Nasdaq: MDGS) (“Medigus”), a technology company engaged in innovative internet technologies, electric vehicle and charging solutions and advanced medical solutions, today announced financial results for the six-month periods ended June 30, 2023.

H1 2023 and recent highlights:

Medigus’ revenues reached $53.3 million in the first six months of 2023, compared to $35 million in the first six months of 2022, representing a 52% increase;

Medigus’ subsidiary for EV Wireless Charging, Charging Robotics, merged with a public company in the US and commenced trading on the OTC Market (OTCMKTS: FDOC);
Medigus sold its entire stake in Odysight.ai Inc. (formerly known as Scoutcam Inc.) for approximately $5.7 million in cash;
Drone safety company, ParaZero (PRZO), commenced trading on Nasdaq, following a $7.8 million initial public offering (”IPO”);
Jeffs’ Brands (JFBR) revenues for the first six months of 2023 totaled $3.9 million, compared to $2.3 million in the first six months of 2022, representing a 65% increase;
Viewbix (OTC: VBIX) reported its condensed consolidated financial results for the first half of 2023 with revenues totaling $48 million, an increase of 10% compared to the first half of 2022; and
Eventer’s revenues for the first six months of 2023 amounted to approximately $1.5 million with net profit for the first time.

We are thrilled to report a great first half of 2023 for Medigus. Our revenue growth, reaching $53.3 million, showcases a substantial 52% increase compared to the same period last year, reflecting our team’s unwavering commitment to excellence and strategic foresight,” said Liron Carmel, Chief Executive Officer of Medigus. “The successful IPO of ParaZero, exciting merger of our subsidiary, Charging Robotics, with a US public company and the sale of our Odysight.ai Inc stake are all testaments to our strategic moves to optimize shareholder value.”

Mr. Carmel added, “We’re also pleased with Viewbix’s commendable performance. As we move forward, the expiration of all our listed warrants ensures a simplified capital structure in addition to our cash boost as a result of the sale of Odysight.ai Inc. At Medigus, we are always striving to pioneer, innovate, and grow, and we remain excited for what the future holds for our company and our stakeholders.”

The Company’s gross profit for the first half of 2023 was approximately $8.2 million, compared to a gross profit of approx. $6.1 million in the first half of 2022. Operating loss for the six months ended on June 30, 2023, was $9.8 million, compared to operating loss for the six months ended on June 30, 2022, of approx. $6.3 million.

About Medigus

Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology company focused on innovative growth partnerships, engaged in innovative internet technologies, electric vehicle and charging solutions and advanced medical solutions. Medigus’ affiliations in the medical solutions arena include ownership in Polyrizon Ltd. The Company’s affiliates in digital commerce include Gix Internet Ltd., Jeffs’ Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle market, Charging Robotics Ltd. and Revoltz Ltd. by way of Fuel Doctor Holdings, Inc., are also part of the Company’s portfolio of technology solution providers. Medigus is traded on the Nasdaq Capital Market. To learn more about Medigus’ advanced technologies, please visit http://www.medigus.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Because such statements deal with future events and are based on Medigus’ current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Medigus could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Medigus undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Medigus is not responsible for the contents of third-party websites.

Company Contact:

Tali Dinar
Chief Financial Officer
+972-8-6466-880
[email protected]

Investor Relations Contact:

Michal Efraty
Investor Relations, Israel
+972-(0)52-3044404
[email protected]

MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	June 30, 2023		December 31, 2022
	Unaudited		Audited
	USD in thousands

ASSETS

CURRENT ASSETS:
Cash and cash equivalents		12,359		20,065
Short term deposits		11		859
Restricted cash		182		185
Trade accounts receivable		18,981		21,449
Receivable from sale of shares		5,774		–
Other receivables		2,015		1,928
Inventory		2,543		1,791
Loans to associates		1,181		546
Loans to others		1,017		1,011
Related parties		238		298
Financial assets at fair value through profit or loss		2,243		4,126
		46,544		52,258

NON-CURRENT ASSETS:
Property and equipment, net		384		408
Right-of-use assets, net		598		591
Investments accounted for using the equity method		5,454		11,892
Intangible assets, net		31,036		30,862
Deferred tax asset		458		397
Financial assets at fair value through profit or loss		1,193		1,243
		39,123		45,393

TOTAL ASSETS		85,667		97,651

MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

	June 30, 2023			December 31, 2022
	Unaudited			Audited
	USD in thousands

LIABILITIES AND EQUITY

CURRENT LIABILITIES:
Trade accounts payable		18,587			20,421
Short term loans		5,973			5,111
Current portion of long-term loans		1,879			1,500
Lease liabilities		165			131
Warrants at fair value		158			396
Liability to event producers		1,526			1,654
Warrants at fair value issued by a subsidiary		3,142			4,159
Related parties		811			1,055
Accrued expenses and other current liabilities		3,638			3,200
		35,879			37,627

NON-CURRENT LIABILITIES:
Lease liabilities		447			512
Long-term loans		3,128			2,881
Deferred tax liability		1,747			1,817
Accrued severance pay, net		19			125
		5,341			5,335

TOTAL LIABILITIES		41,220			42,962

EQUITY:
Share capital – ordinary shares with no par value: authorized – June 30,2023 – 200,000,000 and December 31, 2022 – 200,000,000 shares; issued and outstanding – June 30, 2023 – 25,524,570 shares December 31, 2022 – 24,661,470 shares		–			–
Share premium		111,589			111,322
Other capital reserves		13,763			13,208
Warrants		197			197
Accumulated deficit		(93,786	)		(85,586	)
Equity attributable to owners of Medigus Ltd.		31,763			39,141
Non-controlling interests		12,684			15,548
		44,447			54,689

TOTAL LIABILITIES AND EQUITY		85,667			97,651

MEDIGUS LTD.

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF LOSS
AND OTHER COMPREHENSIVE LOSS

	Six months ended June 30,
	2023			2022
	Unaudited
	USD in thousands
Revenues
Products		3,871			2,343
Services		49,514			32,616
		53,385			34,959

Cost of revenues:
Products		3,497			1,933
Services		41,688			26,834
		45,185			28,767

Gross profit		8,200			6,192
Research and development expenses		2,632			2,500
Sales and marketing expenses		1,868			2,240
General and administrative expenses		8,274			5,057
Net change in fair value of financial assets at fair value through profit or loss		3,978			813
Equity losses		1,238			1,910
Operating loss		(9,790	)		(6,328	)

Gain from initial recognition of assets and liabilities upon consolidation of Gix Internet		–			(2,300	)
Loss from sale of investments		–			(68	)
Other income		(154	)		(176	)
Changes in fair value of warrants issued to investors		(238	)		99
Changes in fair value of warrants issued to third party investors by a consolidated subsidiary		(1,017	)		63
Financial loss, net		978			793
Loss before taxes on income		(9,359	)		(4,739	)
Tax expenses		(177	)		(9	)
Net loss for the period		(9,536	)		(4,748	)

Other comprehensive income (loss)
Items that may be reclassified to profit or loss
Share of other comprehensive income (loss) of consolidated subsidiaries and associates accounted for using the equity method		306			(961	)
Other comprehensive income (loss) for the period		306			(961	)
Total comprehensive loss for the period		(9,230	)		(5,709	)

Net loss for the period is attributable to:
Owners of Medigus		(8,200	)		(3,590	)
Non-controlling interests		(1,336	)		(1,158	)
		(9,536	)		(4,748	)
Total comprehensive loss for the period is attributable to:
Owners of Medigus		(8,061	)		(4,275	)
Non-controlling interests		(1,169	)		(1,434	)
		(9,230	)		(5,709	)
Loss per ordinary share attributed to Medigus ltd
Basic		(0.33	)		(0.15	)
Diluted		(0.33	)		(0.15	)

Weighted average ordinary shares outstanding (in thousands)
Basic		24,490			24,109
Diluted		24,490			24,109

September 28, 2023 8:07 pm

Dime Community Bancshares Declares Quarterly Cash Dividend for Common Stock

HAUPPAUGE, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors today declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on October 24, 2023 to common stockholders of record as of October 17, 2023. The Company continues its trend of uninterrupted dividends.

ABOUT DIME COMMUNITY BANCSHARES, INC.

Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust company with over $13.8 billion in assets and the number one deposit market share among community banks on Greater Long Island ⁽¹⁾.

Dime Community Bancshares, Inc.

Investor Relations Contact:
Avinash Reddy
Senior Executive Vice President – Chief Financial Officer
Phone: 718-782-6200; Ext. 5909
Email: [email protected]

¹ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets.

September 28, 2023 8:05 pm

JBG SMITH Receives 2023 Leadership Award for Outstanding Commitment to the Advancement of Green Building

JBG SMITH Receives 2023 Leadership Award for Outstanding Commitment to the Advancement of Green Building

BETHESDA, Md.–(BUSINESS WIRE)–
JBG SMITH (NYSE: JBGS), a leading owner and developer of high-quality, mixed-use properties in the Washington, DC market, was presented today with the Leadership Award for Organizational Excellence by the U.S. Green Building Council (USGBC) at their annual Greenbuild Conference.

The Leadership Award for Organizational Excellence is given to outstanding organizations whose vision, leadership, and commitment have significantly advanced the green building industry. JBG SMITH was chosen as one of this year’s honorees for its efforts as a sustainability leader and model in the real estate sector, demonstration of environmental responsibility through maximized operational efficiency, minimized waste, and prioritization of renewable energy. The company has made bold commitments to maintain portfolio-wide carbon neutrality and continues to prioritize and earn LEED certification for its new developments.

“We’re honored to be recognized as a leader in sustainability and green building by the USGBC, an organization so fundamental to the future of the real estate industry and the impact it has on our planet,” said Matt Kelly, JBG SMITH Chief Executive Officer. “Environmental sustainability has been a core part of our business for years, and we strive to lead by example and ensure our strategic plans align with sustainability best practices at all levels.”

The focus for JBG SMITH in the coming years will be on performance achievements across energy, water, waste, and GHG reductions. Added Kim Pexton, Senior Vice President of Sustainability, “The remainder of the decade must be laser-focused on results. This can only be achieved through integration at every level of the organization.”

About JBG SMITH

JBG SMITH owns, operates, invests in, and develops mixed-use properties in high growth and high barrier-to-entry submarkets in and around Washington, DC. Through an intense focus on placemaking, JBG SMITH cultivates vibrant, amenity-rich, walkable neighborhoods throughout the Washington, DC metropolitan area. Approximately two-thirds of JBG SMITH’s holdings are in the National Landing submarket in Northern Virginia, which is anchored by four key demand drivers: Amazon’s new headquarters; Virginia Tech’s under-construction $1 billion Innovation Campus; the submarket’s proximity to the Pentagon; and JBG SMITH’s deployment of next-generation public and private 5G digital infrastructure. JBG SMITH’s dynamic portfolio currently comprises 15.0 million square feet of high-growth office, multifamily, and retail assets at share, 98% of which are Metro-served. It also maintains a development pipeline encompassing 9.8 million square feet of mixed-use, primarily multifamily, development opportunities. JBG SMITH is committed to the operation and development of green, smart, and healthy buildings and plans to maintain carbon neutral operations annually. For more information on JBG SMITH please visit www.jbgsmith.com.

About the U.S. Green Building Council (USGBC)

The U.S. Green Building Council (USGBC) is committed to a prosperous and sustainable future through cost-efficient and energy-saving green buildings. USGBC works toward its mission of market transformation through its LEED green building program, robust educational offerings, an international network of local community leaders, the annual Greenbuild International Conference & Expo, the Center for Green Schools, and advocacy in support of public policy that encourages and enables green buildings and communities. For more information, visit usgbc.org.

Forward-Looking Statements

Certain statements contained herein may constitute “forward-looking statements” as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not guarantees of performance. They represent our intentions, plans, expectations, and beliefs and are subject to numerous assumptions, risks, and uncertainties. Consequently, the future results of JBG SMITH Properties (“JBG SMITH”) may differ materially from those expressed in these forward-looking statements. You can find many of these statements by looking for words such as “approximate”, “believes,” “expects,” “anticipates,” “intends,” “plans,” “proposed,” “would,” “should,” “may,” or similar expressions in this press release. We also note the following forward-looking statements: future sustainability metrics and plans. Many of the factors that will determine the outcome of these and our other forward-looking statements and plans are beyond our ability to control or predict. These factors include, among others: adverse economic conditions in the Washington, DC metropolitan area, the timing of and costs associated with development and property improvements, financing commitments, and general competitive factors. For further discussion of factors that could materially affect the outcome of our forward-looking statements and other risks and uncertainties, see “Risk Factors” and the Cautionary Statement Concerning Forward-Looking Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports the Company files with the Securities and Exchange Commission. For these statements, we claim the protection of the safe harbor for forward looking statements contained in the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on our forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions to our forward-looking statements after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928580816/en/

Media

Bud Perrone

Rubenstein

Managing Director

(212) 843-8068

[email protected]

Samantha Schmieder

JBG SMITH

Corporate Communications Manager

(240) 333-7706

[email protected]

KEYWORDS: District of Columbia Maryland United States North America

INDUSTRY KEYWORDS: Environmental Health Urban Planning REIT Landscape Interior Design Architecture Other Construction & Property Residential Building & Real Estate Commercial Building & Real Estate Construction & Property Alternative Energy Energy Green Technology Sustainability Building Systems Environment Environmental Issues

MEDIA:

Logo

September 28, 2023 8:03 pm

Dime Community Bancshares Inc. Announces Retirement of Marcia Z. Hefter from Board of Directors

HAUPPAUGE, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (NASDAQ: DCOM) (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) announced today that Marcia Z. Hefter is retiring from the Board of Directors, effective September 28, 2023.

Ms. Hefter began her career with the Company and the Bank as a Director of Bridgehampton National Bank (predecessor of BNB Bank) in 1989 and served as the Board Chairwoman from 2008 to 2021. Ms. Hefter’s background as a lawyer and long-standing service as a director provided the Board of Directors with a unique perspective and counsel in its oversight of the Company. Following the closing of the Company’s merger of equals transaction in 2021, Ms. Hefter was appointed Lead Director.

“Marcia’s contribution and passion for our company has been unmatched during her tenure since joining the board over three decades ago,” said Lead Director Dennis A. Suskind of Dime. “She has led the institution through unprecedented growth since joining Bridge Bancorp in 1989, when we were $94.4 million in assets. She has been integral in the transformation from what was an East End Bank to a Community Bank spanning Montauk to Manhattan, through the merger, and our growth to what we are today, 59 branches in locations from Montauk to Manhattan. In her role as Chairperson and as Lead Director, she has provided great counsel and leadership to the entire board. On behalf of the entire Board of Directors, I thank her for her dedication and service and wish her well as she embarks in new challenges.”

Executive Chairman Mahon commented, “Director Hefter brought a professional demeanor to our board table and provided thoughtful input to our deliberations as we merged our two legacy institutions over the past two years. She will be missed by her fellow directors, and we wish her all health and happiness in the future.”

Ms. Hefter stated, “I am privileged to have participated in the historic growth and success of Bridgehampton National Bank into its merger with Dime Community Bank. I leave the Board of Directors with the knowledge that the future of Dime is robust and in excellent hands.”

ABOUT DIME COMMUNITY BANCSHARES, INC.
Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, a New York State-chartered trust company with over $13.8 billion in assets and the number one deposit market share among community banks on Greater Long Island ⁽¹⁾.

Dime Community Bancshares, Inc.

Investor Relations Contact:
Avinash Reddy
Senior Executive Vice President – Chief Financial Officer
Phone: 718-782-6200; Ext. 5909
Email: [email protected]

⁽¹⁾ Aggregate deposit market share for Kings, Queens, Nassau & Suffolk counties for community banks with less than $20 billion in assets.

September 28, 2023 7:58 pm

Medicenna Announces Results of Annual and Special Meeting of Shareholders

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company’s annual and special meeting of shareholders held today, September 28, 2023 (the “Meeting”).

Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote are detailed below:

Nominee	Votes For	% of Votes For	Votes Against	% of Votes Against
Dr. Fahar Merchant	22,494,932	97.816%	502,208	2.184%
Mr. Albert Beraldo	22,509,538	97.880%	487,602	2.120%
Ms. Karen Dawes	22,598,451	98.266%	398,689	1.734%
Dr. John (Jack) Geltosky	22,543,861	98.029%	453,279	1.971%
Dr. John Sampson	22,611,787	98.324%	385,353	1.676%

Ms. Rosemina Merchant and Dr. Chandrakant Panchal decided not to stand for re-election at the Meeting. Ms. Merchant remains the Chief Development Officer of the Company. Mr. Albert Beraldo, Lead Independent Director, commented: “On behalf of my fellow board members and the Medicenna management team, I would like to thank Rosemina and Chandra for their service to the Company over the past years.”

The shareholders approved the adoption of an amendment to the Company’s articles to effect a reverse stock split of the Company’s outstanding common shares at a ratio in the range of 1-for-5 to 1-for-15 (the “Reverse Stock Split”), all as more particularly described in the Circular and subject to the determination by the Board of Directors to implement the Reverse Stock Split. If the Board of Directors determines at a later date to implement such Reverse Stock Split, the Company would then announce a Reverse Stock Split ratio and the anticipated effective date of the Reverse Stock Split.

A Reverse Stock Split would reduce the total number of Medicenna’s issued and outstanding common shares, which is expected to result in an increase in the trading price per share. A Reverse Stock Split is primarily intended to ensure that the Company regains compliance with the minimum required closing bid price for continued listing on the Nasdaq. The Company’s management is evaluating all possible options to regain compliance with Nasdaq requirements. The Reverse Stock Split will be implemented only if the Board of Directors considers it in the best interests of the Company.

Medicenna shareholders also voted for the appointment of PricewaterhouseCoopers LLP as auditor of the Company and the approval of the unallocated options under the Company’s stock option plan. A total of 48.457% of the issued and outstanding common shares of the Company were represented in person and by proxy at the Meeting.

Please refer to the Circular available on SEDAR+ at www.sedarplus.ca for more information on the business transacted at the Meeting. A report on voting results will also be filed on SEDAR+.

About Medicenna

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class class-empowered superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™ program, (Bifunctional SuperKine ImmunoTherapies) is designed to enhance the ability of Superkines to treat immunologically “cold” tumors.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws that relate to the future operations of the Company, plans and projections and other statements, including statements relating to the Reverse Stock Split. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially”, “equivocally,” and similar expressions and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest Annual Information Form and Annual Report on Form 20-F of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada and the United States.

The effect of a Reverse Stock Split, if implemented, on the trading price of our common shares cannot be predicted with any certainty, and the outcomes of reverse stock splits for other companies are varied, particularly given that investors may view a reverse stock split as a negative indicator. It is possible that the trading price of our common shares after a Reverse Stock Split would not increase in the same proportion as the reduction in the number of our outstanding common shares following the Reverse Stock Split or at all. There can be no assurance that if a reverse stock split is implemented, that the Company will regain compliance with the requirements for continued listing on Nasdaq.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

Further Information & Investor Contact:

For further information about the Company please contact:

Delphine Davan
Vice President, Investor Relations and Corporate Communications,
Phone: +1 (647) 474-2641
[email protected]

September 28, 2023 7:56 pm

MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions

MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions

SAN DIEGO–(BUSINESS WIRE)–
MEI Pharma, Inc. (Nasdaq: MEIP) (the “MEI” or “the Company”) today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC.

The MEI Board of Directors and management team are focused on advancing our two programs, voruciclib and ME-344, both on the cusp of reporting clinical data during the first half of 2024 that could support value creation opportunities for the benefit of all stockholders. Each program holds the potential, in combination with current therapies, to overcome known resistance mechanisms and improve patient outcomes in cancer. As we highlighted in our recent earnings disclosures, both programs have generated strong engagement among our clinical investigators, and are supported by data showing potential anti-tumor activity and mechanistic proof-of-concept for the combinations being evaluated.

This is an important time for our Company, and our Board comprises highly qualified directors that bring the broad and diverse experience and expertise needed to provide strong oversight and guide the business forward as MEI executes on its upcoming key milestones. Our Board is focused on value creation and routinely evaluates its capital allocation priorities to ensure MEI is positioning opportunities to deliver the highest returns to stockholders.

In contrast, in their latest filing, Anson and Cable Car are clear in their agenda: they want the Company’s cash regardless of the opportunity cost to MEI’s development programs and other stockholders. Don’t be misled by the claims of Anson and Cable Car.

The plan that Anson and Cable Car lay out to strip the Company of its cash now and replace it with the hope to obtain financing later demonstrates a lack of understanding of our business and the realities of today’s capital markets – and exposes the lack of appreciation of the potential of the programs contrasted with their self-interested desire for a return of capital. We believe our stockholders should be highly concerned that this self-interested group wants to take control of your investment.

Further, if Anson and Cable Car are successful in their consent solicitation and upcoming proxy fight, it would create a sudden and significant disruption in the governance function of MEI and cripple the Company’s ability to leverage the potential to create value from the expected upcoming data readouts from both programs.

Additionally, the MEI Board have evaluated Anson and Cable Car’s latest request to set a new record date and determined there was no basis for doing so. The Company set a record date of August 11, 2023 complying with the express request of Anson and Cable Car, made on August 4, 2023, that a record date be set “immediately, and in no event more than ten (10) days” after such request. The Company then conducted multiple discussions with Anson and Cable Car with the goal of reaching a mutual resolution. On September 13, 2023, Anson and Cable Car by letter unilaterally ended the discussions and terminated the agreement that the Company had with them regarding the conduct of the discussions, in which the Company had committed to make a public response to their consent solicitation promptly following the end to such discussions. Pursuant to that agreement, the Company promptly filed our preliminary materials on September 15, 2023. Consequently, the record date that was set at the express request of Anson and Cable Car for their consent solicitation remains August 11, 2023. MEI stockholders of record as of the close of business on this date are eligible to execute, withhold and revoke written consents in connection with Anson and Cable Car’s proposal.

The MEI Board of Directors and management team will continue to take actions that it believes represent the best interest of ALL MEI stockholders.

The MEI Board will provide its formal recommendation with respect to the consent solicitation in its definitive consent solicitation materials that will be filed with the Securities and Exchange Commission (“SEC”) in the coming days. Additionally, the Board will present its recommendation with respect to the election of directors in the Company’s proxy statement, which will be filed with the SEC and mailed to all stockholders eligible to vote at the Company’s fiscal year 2024 Annual Meeting of Stockholders.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer therapies. We build our pipeline by acquiring promising cancer agents and creating value in programs through development, strategic partnerships, out-licensing and commercialization, as appropriate. Our approach to oncology drug development is to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.

Important Information and Where to Find It:

This statement is neither a solicitation of a proxy or consent nor a substitute for any proxy statement or other filings that may be made with the Securities and Exchange Commission (the “SEC”). Nonetheless, the Company, its directors and/or its director nominees and certain of its executive officers and employees may be deemed to be participants in the solicitation of revocations of consents relating to (i) the efforts of Cable Car Capital LLC (“Cable Car Capital” and, together with its affiliates, “Cable Car”), Anson Advisors Inc. (“Anson Advisors” and, together with its affiliates, “Anson”) and certain other participants to solicit consents for the removal of all members of the Company’s Board, or (ii) proxies from the Company’s stockholders in connection with the fiscal year 2024 Annual Meeting. The Company plans to file with the SEC (i) a consent revocation statement in connection with the solicitation of consents to remove the members of the Board (the “Consent Revocation Statement”) and (ii) a proxy statement in connection with the solicitation of proxies for the fiscal year 2024 Annual Meeting (the “Fiscal 2024 Proxy Statement”).

STOCKHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT AND THE FISCAL 2024 PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Consent Revocation Statement or Fiscal 2024 Proxy Statement and other materials to be filed with the SEC in connection with the consent solicitation or the fiscal year 2024 Annual Meeting. Such information can also be found in the Company’s definitive proxy statement for the fiscal year 2023 Annual Meeting of Stockholders, filed with the SEC on October 27, 2022, the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023, filed with the SEC on September 26, 2023, and in the Company’s Current Reports on Form 8-K filed with the SEC from time to time. To the extent holdings of the Company’s securities have changed since the amounts shown in the definitive proxy statement for the fiscal year 2023 Annual Meeting of Stockholders, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Updated information regarding the identities of potential participants and their direct or indirect interests, by security holdings or otherwise, in the Company will be set forth in the Fiscal 2024 Proxy Statement and other relevant documents to be filed with the SEC, if and when they become available.

Stockholders will be able to obtain, free of charge, copies of the Consent Revocation Statement and the Fiscal 2024 Proxy Statement (including any amendments or supplements thereto) and any other documents filed by the Company with the SEC in connection with the consent solicitation or the Fiscal 2024 Annual Meeting at the SEC’s website (www.sec.gov) or the Company’s investor website at https://www.meipharma.com/investors.

Forward-Looking Statements

Certain information contained in this statement that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding: the director nominations discussed above, the potential, safety, efficacy, and regulatory and clinical progress of our product candidates, including the anticipated timing for initiation of clinical trials and release of clinical trial data and our expectations surrounding potential regulatory submissions, approvals and timing thereof, our business strategy and plans; the sufficiency of our cash, cash equivalents and short-term investments to fund our operations. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to our failure to successfully commercialize our product candidates; the availability or appropriateness of utilizing the FDA’s accelerated approval pathway for our product candidates; final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; costs and delays in the development and/ or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; our inability to maintain or enter into, and the risks resulting from, our dependence upon collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928314455/en/

David A. Walsey

858-369-7104

[email protected]

Joele Frank, Wilkinson Brimmer Katcher

Dan Katcher / Aaron Palash

212-355-4449

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

September 28, 2023 7:54 pm

Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day

Quanterix CEO to Speak at Goldman Sachs Alzheimer’s Disease Day

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer’s Disease Day on Tuesday, October 3, 2023. The panel, Infrastructure considerations: Outlook for blood-based testing, will be held at 12:15 p.m. ET and is accessible to virtual participants by registering here. The presentation will be available for viewing following the conference on Quanterix’s website here: ir.quanterix.com.

To learn more about Quanterix, visit www.quanterix.com/company/.To learn more about Quanterix’s Simoa® technology, visit: www.quanterix.com/simoa-technology/.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa®^{technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,000 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.}

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928005095/en/

Media:

PAN Communications

Maya Nimnicht

510-334-6273

[email protected]

Investor Relations:

Ed Joyce

610-306-9917

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Supplies Biotechnology Health General Health Biometrics Oncology Health Technology Research Infectious Diseases Genetics Science

MEDIA:

Logo

September 28, 2023 7:53 pm

Enterprise to Participate in Wolfe Research Utilities, Midstream & Clean Energy Conference

Enterprise to Participate in Wolfe Research Utilities, Midstream & Clean Energy Conference

HOUSTON–(BUSINESS WIRE)–
Enterprise Products Partners L.P. (NYSE: EPD) announced today it will host virtual investor meetings at the Wolfe Research Utilities, Midstream & Clean Energy Conference on Friday, September 29, 2023.

The latest investor deck that may be used to facilitate the investor meetings can be accessed under the Investors tab on the Enterprise website.

Enterprise Products Partners L.P. is one of the largest publicly traded partnerships and a leading North American provider of midstream energy services to producers and consumers of natural gas, NGLs, crude oil, refined products and petrochemicals. Services include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage and marine terminals; crude oil gathering, transportation, storage and marine terminals; petrochemical and refined products transportation, storage and marine terminals; and a marine transportation business that operates on key U.S. inland and intracoastal waterway systems. The partnership’s assets currently include more than 50,000 miles of pipelines; over 260 million barrels of storage capacity for NGLs, crude oil, petrochemicals and refined products; and 14 billion cubic feet of natural gas storage capacity. Please visit www.enterpriseproducts.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928756368/en/

Randy Burkhalter, Investor Relations, (713) 381-6812 or (866) 230-0745, [email protected]

Rick Rainey, Media Relations, (713) 381-3635, [email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Finance Oil/Gas Energy Professional Services Other Energy

MEDIA:

Logo